New York, March 04, 2024 - PRISM MediaWire - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has obtained Institutional Review Board (IRB) approval to advance its Phase 1 clinical trial of DA-1726, targeting obesity treatment. Anticipated commencement of patient randomization is slated for the second quarter of 2024.
"This promising cardiometabolic asset may exhibit a superior tolerability profile compared to presently available GLP-1 agonists owing to its balanced activation of GLP1R and glucagon receptors. As previously documented, in murine models, DA-1726 demonstrated enhanced weight loss in contrast to semaglutide (Wegovy®), while its administration yielded comparable weight reduction despite increased food consumption compared to tirzepatide (Zepbound™)."
Hyung Heon Kim, President and Chief Executive Officer of NeuroBo
Key Points:
- NeuroBo's Phase 1 trial will comprise a randomized, placebo-controlled, double-blind, two-part investigation aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of DA-1726 in obese yet otherwise healthy subjects.
- The company anticipates releasing top-line data from the single ascending dose Part 1 during the first half of 2025 and from the multiple ascending dose Part 2 in the latter half of the same year.
- Exploratory endpoints will encompass assessing the impact of DA-1726 on metabolic parameters, cardiac parameters, fasting lipid levels, body weight, waist circumference, and body mass index (BMI).
- DA-1726 represents a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR).
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.
About PRISM MediaWire:
PRISM MediaWire provides access to leading financial and trade media outlets, along with key trading platforms. This positions companies at the center of financial market dialogues and trends, providing significant visibility in the competitive capital markets. PRISM MediaWire’s distribution service is further augmented by:
- 24/7 Support: Clients benefit from round-the-clock access to PRISM MediaWire's dedicated support team, ensuring timely assistance is always available.
- Competitive Pricing: PRISM MediaWire offers its top-tier newswire distribution services at competitive rates, providing value for its clients.
- Unlimited Word Count: There are no restrictions on the length of press releases, allowing clients the flexibility to convey their messages comprehensively without word count limitations.
- No Extra Fee for Embedded Images and Videos: PRISM MediaWire enables clients to augment their press releases with images and videos, enhancing their content's visual appeal and engagement, without incurring additional costs.
Learn more about the PRISM Advantage: https://www.youtube.com/watch?v=yk5_Jq8jJPE
Visit our website, prismmediawire.com, and follow us on X.
PRISM MediaWire - Social Media (X)
Contact:
PRISM MediaWire - News & Blog